1365244-33-2

Upstream product

• 1365243-73-7 6,8-dibromo-3-iodoimidazo[1,2-b]pyridazine 
• 1351374-48-5 N-cyclopropyl-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 345965-99-3 4-bromo-N-cyclopropyl-2-methylbenzamide 
• 933190-51-3 8-bromo-6-chloro-imidazo[1,2-b]pyridazine 
• 1263425-59-7 8-bromo-6-chloro-3-iodoimidazo[1,2-b]pyridazine 
• 1365244-31-0 6-bromo-3-iodo-8-(methylsulfanyl)imidazo[1,2-b]pyridazine 
• 1365244-30-9 4-[6-bromo-8-(methylsulfanyl)imidazo[1,2-b]pyridazin-3-yl]-N-cyclopropyl-2-methylbenzamide 
• 1206487-36-6 6,8-dibromoimidazo[1,2-b]pyridazine 

Relevant academic research and scientific papers

COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER

The present invention relates to a combination comprising an Mps-1 kinase inhibitor and a mitotic inhibitor. The present invention also relates to the use of said combination for the treatment of cancer, in particular of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.